CURRICULUM VITAE
Walter L. Longo MD
Walter L. Longo MD
Professor
Department of Medicine
Division of Medicine Hematology Oncology
Department of Medicine
Division of Medicine Hematology Oncology
OFFICE ADDRESS: |
9200 West Wisconsin Avenue |
Milwaukee, WI 53226 |
Fax: 4148054606 |
EDUCATION: |
1971 - 1974 Bachelors of Science, University of Notre Dame, South Bend, IN |
1974 - 1977 M.D., University of Nebraska Medical Center, Omaha, NE |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
1977 - 1980 Resident, The Mayo Graduate School of Medicine, Rochester, MN |
1982 - 1984 Hematology Fellow, University of Wisconsin, Madison, WI |
1984 - 1986 Oncology Fellow, University of Wisconsin, Madison, WI |
FACULTY APPOINTMENTS: |
1980 - 1983 General Internist, Longo Family Practice, Omaha, NE |
1983 - 1986 Clinical Instructor, University of Wisconsin, Madison, WI |
1986 - 1989 Assistant Professor of Medicine, University of Wisconsin, Madison, WI |
1986 - 2017 Clinical Director of Adult Bone Marrow Transplant, University of Wisconsin, Madison, WI |
1989 - 1999 Associate Professor of Medicine, University of Wisconsin, Madison, WI |
1999 - 2018 Professor of Medicine, University of Wisconsin, Madison, WI |
ADMINISTRATIVE APPOINTMENTS: |
1998 - 2017 Clinical Director Bone Marrow Transplant, University of Wisconsin, Madison, WI |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
2000 - 2017 Annual Lecturer for BMT Nursing Orientation and Core Curriculum, University of Wisconsin, Madison, WI |
HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS: |
1988 - 1994 Carbone Cancer Center Operations Committee, University of Wisconsin, Madison, WI |
2015 - 2017 DYAD Leader, University of Wisconsin, Madison, WI |
RESEARCH ADMINISTRATIVE APPOINTMENTS: |
1998 - 2017 BMT QA Committee Chair, University of Wisconsin, Madison, WI |
HOSPITAL STAFF PRIVILEGES: |
1982 - 2018 University of Wisconsin Hospital and Clinics, Madison, WI |
1998 - 2018 Divine Savior Hospital, Portage, WI |
2018 - Present Froedtert Memorial Lutheran Hospital, Milwaukee, WI |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
American Board of Internal Medicine | 1983 | 2023 |
American Board of Oncology | 1987 | 2027 |
Licensure | Number | Issue Date | Expiration |
Nebraska | 13884 | 1977 | 1990 |
Minnesota | 24208 | 1978 | 1983 |
Wisconsin | 24712 | 1982 | 2025 |
AWARDS AND HONORS: |
1971 Regents' Scholarship, University of Nebraska |
1974 - 1975 Dean's List 6 of 6 semesters, Notre Dame |
1975 B.S. Magna Cum Laude, Notre Dame |
1975 Alpha Epsilon Delta, Honorary Pre-Professional Society , Notre Dame |
1980 Dean's Committee on Academic Progress, Notre Dame |
1982 - 1984 American Cancer Society Clinical Fellowship, University of Wisconsin |
1994 Sharon K Bouchard Lecture Award, Gunderson Medial Foundation Ltd |
2011 - Present Best Doctor, Best Doctors in America |
2014 Physician Champion Award, University of Wisconsin |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
1983 - Present American College of Physicians (Member ) |
1985 - Present American Society of Clinical Oncology (Member ) |
1985 - Present American Society of Hematology (Member) |
1988 - Present American Society for Blood and Marrow Transplantation (Member ) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
1990 - Present Journal of Clinical Oncology |
1990 - Present Annals of Internal Medicine |
1990 - Present Wisconsin State Journal |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
1980 - 2017 Committee Member, Hematology/Bone Marrow Transplant Quality Assurance, University of Wisconsin |
1980 - 2000 Member, Peer Review Committee, University of Wisconsin |
1987 - 1988 Committee Member, Clinical Affairs, University of Wisconsin |
2006 - 2018 Board Member, Chartwell Medical Advisory Board, University of Wisconsin |
2012 - 2016 Board Member, Transplant House, University of Wisconsin |
2013 - 2016 Member, Survivorship Committee, University of Wisconsin |
2014 - 2017 Committee Member, Oncology Clinic Operations Committee, University of Wisconsin |
2015 - 2018 Committee Member, Light the Night, Leukemia/Lymphoma Society |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2017 - Present Member, CTN Committee, Clinical Trials Network |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
National |
Walter Longo, RD McCroskey, A phase II study of short course, high does ara-c, cisplatinum, and VP-16 (Etoposide) (ACE) for advanced chronic leukemia or well differentiated lymphocytic lymphoma, American Society of Hematology, 1987 |
Walter Longo, BG Baranski, R Robins, B Schwartz, Phase II study, thiotepa, and VP-16 (Etoposide) in bone marrow ablative doses followed by autologous bone marrow rescue in patients with recurrent hodgkin's disease and non-hodgkin's lymphoma, American Society of Hematology, 1991 |
S Wiersma, Walter Longo, David Spriggs, A Phase II study on continuous infusion fludarabine followed by continuous cytonsine, arabinoside, in adults with recurrent or refractory acute non-lymphocytic leukemia, American Society of Hematology, 1992 |
Local |
Grand Rounds, Green Bay, 10/2011 |
Grand Rounds, Green Bay, 05/2013 |
Grand Rounds, UW-Health, 09/25/2013 |
Grand Rounds, Aspirus, 03/2017 |
Grand Rounds, Fox Valley Hematology, 04/10/2017 |
Grand Rounds, Rush, 07/26/2017 |
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
Regional |
New Approaches to Stem Cell Transplant Using T-Cell Seletion to Eliminate Graft vs. Host Disease and Preserve Graft vs. Leukemia, Buckingham Club Annual Chicago Fundraiser, Chicago, IL, 07/2015 |
EXTRAMURAL TEACHING: |
Medical Student Education |
1981 - 2000 University of Wisconsin, Substitute teacher for M2 Hematology Medical Course |
Graduate Student Education |
1995 - 2000 University of Wisconsin, Hematology Course for Physician Assistants |
Resident and Fellow Education |
1982 - 2018 University of Wisconsin, Hematology & Oncology Clinical Inpatient & Outpatient Rotations |
Continuing Medical Education |
2012 - 2018 Pro Health Care, Monthly Clinical Conference |
PROGRAMMATIC DEVELOPMENTS: |
Clinical Programs |
1999 - 2016 Director of FACT Re-Accreditation Site Visit |
COMMUNITY SERVICE ACTIVITIES: |
2010 Creighton University School of Medicine, Project Cura, Physician Mentor and Volunteer, Urubamba, Peru |
2012 - 2014 Board Member of Transplant House |
2012 Creighton University, The Institute for Latin American Concern, Physician Mentor and Volunteer, Santiago, Dominican Republic |
2017 - Present Board Member & Trustee of the Wayne & Eileen Ryan Foundation |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Sondel PM, Bozdech MJ, Trigg ME, Hong R, Finlay JL, Kohler PC, Longo W, Hank JA, Billing R, Steeves R, Flynn B. Additional immunosuppression allows engraftment following HLA mismatched T-cell depleted BMT for leukemia. Transplant Proc 1984; 17:460 1. |
2. Bozdech MJ, Sondel PM, Trigg ME, Longo W, Kohler PC, Flynn B, Billing R, Anderson SA, Hank JA, Hong R. Transplantation of HLA-haploidentical T cell depleted marrow for leukemia: II. Addition of cytosine arabinoside to the pre-transplant conditioning prevents rejection. Exp Hematol 1985; 13:1201 10.PMID 3905427 |
3. Sondel PM, Hank JA, Molenda J, Blank J, Borcherding W, Longo W, Trigg ME, Hong R, Bozdech MJ. Relapse of host leukemic lymphoblasts following engraft¬ment by an HLA mismatched marrow transplant: Mechanisms of escape from the "graft versus leukemia" effect. Exp Hematol 1985; 13:782 90.PMID2931298 |
4. Trigg ME, Billing R, Sondel PM, Exten R, Hong R, Bozdech MJ, Horowitz SD, Finlay JL, Moen R, Longo W, Erickson C, Peterson A. Clinical trial depleting T-lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. Cancer Treat Rep 1985; 69:377 86. PMID3888387 |
5. Neville AJ, Robins HI, Longo WL, Konich K, Gilchrist KM. A case report of leptomeningeal involvement in pancreatic carcinoma following whole body hyperthermia and pancreatic irradiation. Cancer 1986; 1:132 4. |
6. Robins HI, Longo WL, Hugander A, Bozdech M, Schwartz B, Steeves RA, Flynn B, Trigg M, Sondel PM. Whole body hyperthermia combined with total body ir¬radiation and chemotherapy as a preparative regimen for allogeneic bone marrow transplantation. Cancer 1986; 1:180 3. |
7. Mann J, Hafez GR, Longo WL. The role of the spleen in the transdiaphragmatic spread of Hodgkin's disease. Am J Med 1986; 81:959 61. |
8. Shorr RI, Longo WL, Oberley TD, Bozdech MJ, Walker DL. Cytomegalovirus associated tubulo-interstitial nephritis in an allogeneic bone marrow trans¬plant recipient. Ann Intern Med 1987; 107:351 2. |
9. Robins HI, Longo WL, Steeves RA, Lagoni RK, Hugander A, Neville AJ, O'Keefe S, Giese W, Schmitt CL. A pilot study of whole body hyperthermia and local irradiation for advanced non-small cell lung cancer confined to the thorax. Int J Radiat Oncol Biol Phys 1988; 15:427 31. |
10. Robins HI, Longo WL, Lagoni RK, Neville AJ, Riggs C, Schmitt CL, Hugander A, Young C. A phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Res 1988; 48:6587 92. |
11. Robins HI, Longo WL, Steeves RA, Cohen, JD, Schmitt CL, Neville AJ, O’Keefe, S, Lagoni RK, Riggs, S. Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B cell neoplasms: A report of two pilot clinical trials and laboratory investigations. Int J Radiat Oncol Biol Phys 1990; 18:909-20. |
12. Robins HI, Longo WL, Storer B, Schmitt C, Sielaff KM, Grossberg S, Hawkins MJ, Borden EC. A phase I trial of interferon Ly with whole body hyperthermia. Cancer Res 1989; 49:1609 15. |
13. Finlay J, August C, Packer R, Zimmerman R, Sutton L, Nachman J, Levin A, Turski P, Steeves R, Longo W, Javid M. High-dose multi-agent chemotherapy followed by bone marrow "rescue" for malignant astrocytomas of childhood and adolescence.
J Neurooncol 1990; 9:239-48.
|
14. McCroskey RD, Mosher DF, Spencer CO, Prendergast E, Longo WL. Acute tumor lysis syndrome in patients treated for refractory chronic lymphocytic leukemia with short course high dose ARA C, Cisplatin and Etoposide (ACE). Cancer 1990; 66:246-50. |
15. Robins IH, Cohen JD, Schmidt CL, Tutsch KD, Feierabend C, Artzoomanian RZ, Alberti D, d’Oleire F, Longo WL, Heiss C, Rushing D, Love R, Spriggs D. A phase 1 clinical trial of carboplatin and 41.8C whole body hyperthermia in cancer patients. J Clin Oncol 1993; 11:1787-94. |
16. Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d’Oleire F, Qu RP, Stewart JA, Wilding G. A phase I trial of 41.8C whole body hyperthermia and melphalan in cancer patients. J Clin Oncol 1997; 15:158-64. |
17. Vose MM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernandez Ranada JM, Stiff PJ, Tabbara I, Longo WL, Copelan EA, Nichols C, Smith A, Topolsky DL, Biernan PJ, Lebsack ME, Lange M, Garrison L. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous BMT for non-Hodgkin’s lymphoma: results of a randomized double blind trial. J Clin Oncol 1997; 15:1617-23. |
18. Schuening FG, Longo WL, Atkinson ME, Zaboikin M, Kiem HP, Sanders J, Scott CR, Storb R, Miller AD, Reynold T, Bensinger W, Rowley S, Gooley T, Darovsky B, Appelbaum F. Retrovirus-mediated transfer of the cDNA for human glucoceribrosidase into peripheral blood repopulating cells of patients with Gaucher’s disease. Hum Gene Ther 1997; 8:2143-60. |
19. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303-14. |
20. Robins HI, Katschinski DM, Longo W, Grosen E, Wilding G, Gillis W, Kraemer C, Tiggelaar CL, Rushing D, Stewart JA, Spriggs D, Love R, Arzoomanian RZ, Reierabend C, Alberti D, Morgan K, Simon K, d’Oleire F. A pilot study of melphalan, tumor necrosis factor- and 41.8C whole body hyperthermia. Cancer Chemother Pharmacol 1999; 43(5):409-14. |
21. Mineishi S, Longo WL, Atkinson ME, Smith EP, Hamielec M, Wiersma SR, Kinsella TJ, Schuening FG. Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant 1999; 23:1217-22. |
22. Robins HI, Longo W. Whole body hyperthermia: simple complexities. Intensive Care Med 1999 Sep; 25(9):898-900. |
23. Katschinski DM, Wiedemann GJ, Longo W, d’Oleire FR, Spriggs D, Robins HI. Whole body hyperthermia cytokine induction: a review, and a unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine Growth Factor Rev 1999; 10:93-7. |
24. Robins HI, Grosen E, Katschinski DM, Longo W, Tiggelaar CL, Kutz M, Winawer J, Graziano F. Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases. J Rheumatol 1999; 26:2513-6.
|
25. Gordon MS, Young ML, Tallman MS, Cripe LD, Bennett JM, Paietta E, Longo W, Gerad H, Mazza J, Rowe JM. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res. 2000 Oct;24(10):871-5.PMID:10996206 [PubMed - indexed for MEDLINE] |
26. Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ, Kim K, Mosher DF, Wiersma SR, Longo WL. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 2001; 41(3-4):321-31. |
27. Westermann AM, Wiedemann GJ, Jager E, Jager D, Katschinski DM, Knuth A, Vörde sive Vörding PZ, Van Dijk JDP, Finet J, Neumann A, Longo W, Bakhshandeh A, Tiggelaar CL, Gillis W, Bailey H, Peters SO, Robins HI. A Systemic Hyperthermia Oncologic Working Group Trial. Ifosfamide, Carboplatin, and Etoposide combined with 41.8C whole-body hyperthermia for metastatic soft tissue sarcoma. Oncology 2003; 64:312-21. |
28. McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL. A novel preparative regimen for autologous transplant in non-Hodgkin’s lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant 2004; 33:19-24. |
29. Turchin A, Wiebe DA, Seely EW, Graham T, Longo W, Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant 2005; 35:85-9. |
30. Kahl BS, Bailey H, Kim KM, Smith E, Turman N, Smith J, Werndli J, McGovern J, Jumonville A, Williams E, Longo W. Phase II study of weekly Paclitaxel for relapsed and refractory non-Hodgkin’s lymphoma: A Wisconsin Oncology Network Study. Cancer Invest 2005; 23:13-8. |
31. Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, Garry McCoy A, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leuk Lymphoma 2005; 46(10):1441-8. |
32. Robins HI, Brandt K, Longo WL. Pathophysiology and Management of Fever Re-visited. J Support Oncol 2006; (6):265-6. |
33. Kahl BS, Go RS, Rodrigues G, Sanchez FA, Saphner TJ, Werndli JE, Kirkpatrick HM, Longo WL. Phase II study of R-CHOP with GM-CSF cytokine support for elderly patients with untreated diffuse large B-cell lymphoma (DLBCL): A Wisconsin Oncology Network study. J Clin Onc 2006; 24:438S-438S Part 1 Supp. PMID: 21030351 |
34. Kahl B, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W,Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17:1418-1423. |
35. Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl BS. A five-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest 2007; 25:87-93. |
36. Agriantonis DJ, Perlman SB, Longo WL, F-18 FDG PET imaging of GVHD-associated polymyositis. Clin Nucl Med. 2008 Oct;33(10):688-9 PMID 18806568. |
37. Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E: Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematol Oncol 2008, 26:241-246. PMCID: PMC3496178. |
38. Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:2298-2307. PMCID: PMC2844086. |
39. Chang, JE, Juckett, MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL. Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma 2008;8:153-158. PMCID: PMC2913594. |
40. Chang JE, Seo S, Kim KM, Werndli JE, Bottner WA, Rodrigues GA, Sanchez FA, Saphner TJ, Longo WL, Kahl BS. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk. 2010:(5):379-84. doi: 10.3816/CLML.2010.n.071. PMID: 21030351. PMCID: PMC3360541. |
41. Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7. doi: 10.1111/j.1365-2141.2011.08820.x. Epub 2011 Aug 16. PMID 21848883 PMCID: PMC3188692. |
42. Simondsen, KA, Reed MP, Mably MS, Yang, Z, Longo WL. Retrospective analysis of fluoroquinolone prophylazis in patients undergoing allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2013 DEC:19(4):291-7. Doi:10.1177/1078155212465215.. [Epub 2012 Nov 26. PMID: 23184539. PMCID: Policy Exempt – Not resulting from NIH funding. |
43. Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E. Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct;74(4):875-82. doi: 10.1007/s00280-014-2550-5. Epub 2014 Aug 29. PMID: 25168296 |
44. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML; Blood and Marrow Transplant Clinical Trials Network. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-8. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23. PMID: 27118571 PMCID: PMC4949103 |
45. Azari AA, Karadag R, Kanavi MR, Nehls S, Barney N, Kim K, Longo W, Hematti P, Juckett M. Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease. Cutan Ocul Toxicol. 2017 Jun; 36(2):152-156. doi: 10.1080/15569527.2016.1209770. Epub 2016 Jul 22 PMID: 27380960 |
46. Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e61-e67. doi: 10.1016/j.clml.2017.10.006. Epub 2017 Nov 4. PMID: 29191715 |
47. . The 8th World Meeting on Impotence Research. Amsterdam, The Netherlands, 25-28 August 1998. Abstracts. Int J Impot Res. 1998 Aug;10 Suppl 3:S1-72. |
48. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M.. Efficacy of a third SARS-Co V-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR
T cell, and BiTE recipients. Cancer Cell. 40(4):340-342. PMCID: PMC8864440. |
49. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M.. Impact of Chrome Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CART-Cell Therapy in Lymphoma Patients.
Clin Lymphoma Myeloma Leuk. (11l):863-868. |
50. Mohan, M., S. Nagavally, N.N. Shah, L. Michaelis, S. Chhabra, A.D. Souza, S. Abedin, L. Runaas, G.S. Guru Murthy, W. Longo, M. Hamadani, B. Dhakal, P. Hari, and T.S. Fenske
. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk. 22(7): p. e495-e497. |
51. Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Pei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR.
. Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. Haematologica. 108(1):250-256. PMCID: PMC9827178. |
52. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M.
. Severity arid organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 59(3):373-379. |
53. Shah, N.N., E.L. Atallah, S. Abedin, G.S.G. Murthy, L. Runaas, L.C. Michaelis, W. Longo, F. Furqan, D. Bucklan, A. Szabo, T. Kearl, D. Schneider, K. Palen, B.D. Johnson, P. Hematti, T.S. Fenske, and M. Hamadani. Phase I Trial ofLV20.19 CART-Cells for Relapsed, Refractory CLL and Richter's Transformation Transplantation and Cellular Therapy. 30(2, Supplement): p. S35-S36. ORAL. |
54. Abid, M.B., A. Szabo, M. Hamadani, M.B. Graham, P. Hari, J. Jerkins, N.N. Shah, S. Abedin, L. Runaas, W.L. Longo, and S. Chhabra. Severity of Cytokine Release Syndrome As a Predictor of Infections after T-Cell Replete Haploidentical Hematopoietic Cell Transplantation (haploHCT) Biology of Blood and Marrow Transplantation. 25(3): p. S368. POSTER. |
55. Furqan, F., E. Aschenbrenner, J. Talano, A. Moskop, W. Longo, B.D. Johnson, T.S. Fenske, M. Hamadani, and N.N. Shah
. Clinical Characteristics and Patient Outcomes with HLH-like Toxicities after CDl 9 Based CART-Cell Therapy. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy. 29(2): p. S131-S132. POSTER. |
56. Shah, N.N., P.L. Zinzani, M.L. Wang, S.D. Nasta, E. Lech-Maranda, Y. Ogawa, B. Fakhri, B. Kuss, K. Miyashita, K. Patel, C.C. Coombs, S. Ma, M. Patel, M.A. Barve, B. Tessoulin, A. Stathis, W.S. Kim, D. Ennishi, D. Hashimoto, K. Kojima, A.D. Zelenetz, J.B. Cohen, J.M. Vose, K.J. Maddocks, T. Munir, F. Sun, F. Bian, D.E. Tsai, P. Abada, and C.Y. Cheah. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study Blood. 142(Supplement 1): p. 3026-3026. POSTER. |
57. Furqan, F., V. Bhatlapeumarthi, F. Farrukh, T.S. Fenske, W. Longo, N.N. Shah, A.D Souza, M.C. Pasquini, G.S.G. Murthy, L. Runaas, S. Abedin, M. Mohan, B. Dhakal, and M. Hamadani. Outpatient Administration of Commercial antiCD19 and Antibcma Chimeric Antigen Receptor-Modified T-Cell (CAR-T) Therapies Using a Strategy ofNo Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention. Transplantation and Cellular Therapy. 30(2, Supplement): p. S211. POSTER. |
58. Furqan, F., K. Palen, B.D. Johnson, T. Kearl, P. Hematti, W. Longo, M. Hamadani, T. Fenske, and N.N. Shah. Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD 19 (LV20.19) CART-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma Journal of Clinical Oncology. 42(suppl 16; abstr 7043). POSTER. |
59. Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2285-2295. |
60. Aughey E, Shah NN, Hillard CJ, Rentscher KE, Hamadani M, Longo W, Devata S, Knight JM, Cusatis R. Financial Toxicity in a Phase I/II Trial of LV20.19 CAR-T Cell for B-cell Malignancies: A Longitudinal, Qualitative Study. Transplant Cell Ther. 2026 May;32(5):621.e1-621.e11. PMCID: PMC12952239 |
61. Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR. Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2026 Apr 28;10(8):2698-2710. PMCID: PMC13101680 |
Books, Chapters, and Reviews |
1. Longo WL, Carbone P. Chemotherapy administration to the elderly. In: Clinics in Oncology, Vol. 4, No. 3, November 1985. |
2. Sollinger HW, Eckhoff DE, Hullett DA, Knechtle SJ, Longo WL, Mentzer RM, Pirsch JD. The Year Book of Transplantation, 1994 and 1995, Mosby ed. |
3. Robins HI, Longo WL, Storer B, Schmitt C, Sielaff KM, Grossberg S, Hawkins MJ, Borden EC. A phase I trial of interferon- Ly with whole body hyperthermia. In: Sugahara T, Saito M, eds. Hyperthermic Oncology. Taylor & Francis, 1988:378-9. |
4. Robins HI, Longo WL, Schmitt CL, Lagoni RK, Neville AJ, Geise W, Steeves RA. Whole body hyperthermia and total body irradiation in the treatment of B cell neoplasm. In: Sugahara T, Saito M, eds. Hyperthermic Oncology. Taylor & Francis, 1988:507-8. |
5. Longo WL, Howard SP, Heiner JP. Multiple myeloma. In: Heiner JP, Kinsella TJ, Zdeblick TA, eds. Management of metastatic disease to the musculoskeletal system. St. Louis: Quality Medical Publishing, Inc., 2002:247. |
Abstracts |
1. Robins HI, Longo WL, Gillis W, O'Keefe S, Shecterle LM, Hugander AH, Martin PA, Schmidt C, Dennis WH. Preliminary results of a phase I study combining 41.8oC whole body hyperthermia (WBH) and lonidamine (LON). ASCO 1986; 5:36. |
2. Robins HI, Storer B, Longo WL, Sauerssig J, Jendre R, Shecterle LM, Hugander AH, Hawkins MJ, Sielaff KC, Borden EC. Interferon (IFN ) and whole body hyperthermia (WBH): A phase I trial. AACR 1986; 27:205. |
3. Longo WL, Robins HI, Giese W, Havlin K, Lagoni R, DeMets D, Steeves RA. Initial results of phase I study of total body irradiation (TBI) and lonida¬mine (LON) in lymphoid neoplasms. AACR 1986; 27:205. |
4. Robins HI, Longo WL, Lagoni RK, Hugander A, Dennis WH. Results of a phase I study combining 41.8oC whole body hyperthermia (WBH) and lonidamine (LON). Rad Res Soc NAHG, Bf 4, 1987. |
5. Longo WL, Robins HI, Martin PA, Lagoni RK, Giese W, Martino R, Steeves RA. A pilot study of whole body hyperthermia (WBH) and total body irradiation (TBI) in lymphoid neoplasms. Rad Res Soc NAHG, Bf 2, 1987. |
6. Schmitt CL, Robins HI, Peterson C, Steeves RA, Martin PA, Longo WL, Shrivastava P. A hyperthermia study of differential sensitivity and thermo¬tolerance in AKR murine lymphoma and normal bone marrow cells. Rad Res Soc NAHG, Co 8, 1987. |
7. Robins HI, Steeves RA, Longo WL, Lagoni RK, Giese W, Hugander A, O’Keefe S, Neville AJ. A pilot study of whole body hyperthermia (WBH) and local irradiation (XRT) for advanced non-small lung cancer. AACR 1987; 28:883. |
8. Finlay J, Dinndorf P, Sondel P, Longo W, Frierdich S. High-dose thiotepa and VP-16 followed by autologous bone marrow ‘rescue’ in the management of children and young adults with recurrent brain tumors: A pilot study. International Society of Paediatric Oncology SIOP XIX Meeting, Jerusalem, September 13 18, 1987. |
9. Longo WL, McCroskey RD, Williams EC, Mosher DF. Tumor lysis syndrome in chronic lymphocytic leukemia. Blood 1987; 70:203a. |
10. Robins HI, Longo WL, Storer B, Sielaff KC, Lagoni R, Hawkins MJ, Borden EC. Results of a phase 1 trial of whole body hyperthermia (WBH) and human lympho blastoidinterferon (IFN ). 5th International Symposium on Hyperthermic Oncology, Kyoto, Japan, September 1988. |
11. Robins HI, Longo WL, Schmitt CL, Lagoni RL, Neville AJ, Giese W, Steeves RA. Whole body hypothermia and total body irradiation in the treatment of favor¬able B-cell neoplasms. Proceedings of the 5th International Symposium on Hyperthermic Oncology, Kyoto, Japan, 1988. |
12. Robins HI, Longo WL, Storer B, Schmitt C, Sielaff KM, Grossberg S, Hawkins MJ, Borden EC. A phase I trial of interferon Ly with whole body hyperthermia. Proceedings of the 5th International Symposium on Hyperthermic Oncology, Kyoto, Japan, 1988. |
13. Robins HI, Tutsch K, Cohen J, Schmitt C, Longo W, Javid M, Trump D, Bailey H, Arzoomanian R, Tombes M, Alberti D, Spriggs D. Phase I clinical trial of carboplatin (CBDCA) and whole body hyperthermia (WBH). AACR 1990; 31:205. |
14. Robins HI, Cohen JD, Schmitt CL, Arzoomanian R, Tutsch K, Longo WL, Tombes MB, Alberti D, Bailey H, Javid MJ, Spriggs D. Preliminary results of a phase I clinical trial of whole body hyperthermia and carboplatin. Rad Res Soc NAHG, Abs. An-1, 1990. |
15. Robins HI, Cohen JD, Tutsch KD, Schmitt C, Longo W, Javid M, Arzoomanian RZ, Tombes MB, Love RR, Alberti D, Spriggs D. Phase I clinical trial of carboplatin (CBDCA) and whole body hyperthermia (WBH). ASCO 1991; 10:265. |
16. Orzepowski W, Matzke B, Molenda J, Longo W, Baranski B. Pentoxifylline affects the production of myeloid growth factors by mitogen-stimulated peripheral blood and spleen cells. Blood 1991; 78:428a. |
17. Matzke B, Longo W, Hong R, Molenda J, Baranski B. Alloreactive contact-dependent T-cell inhibition of bone marrow progenitor cells requires -interferon. Blood 1991; 78:288a. |
18. Longo W, Hong R, Flynn B, Molenda J, Hamielec M, Robins I, Schwartz, Baranski B. High dose VP16 and high dose Thiotepa is a well-tolerated preparative regimen for autologous bone marrow transplant. Blood 1991; 78:505a. |
19. Robins HI, Cohen JD, Tutsch KD, Schmitt CL, Longo W, Javid M, Arzoomanian RZ, Kuzminsky S, Alberti D, Feierabend C, Spriggs D. A phase I clinical trial of carboplatin (CBDCA) and whole body hyperthermia (WBH). Hyperthermic Oncology, 6th International Symposium. EW Gerner, ed. 1992; 1:418. |
20. Matzke B, Hogendorn C, Longo W, Baranski B. Pentoxifylline decreases the in vitro production of multiple cytokines, including GM-CSF and gamma-interferon. Blood 1992; 80:142a. |
21. Jurgella C, Matzke B, Molenda J, Longo W, Baranski B. Lazaroids obrogate TNF- induced L929 cell cytotoxicity-further evidence for the role of reactive oxygen intermediates in the TNF-induced cell damage. Blood 1992; 80:296a. |
22. Abonour R, Williams EC, Longo W, Wiersma S. Continuous infusion Cytosine Arabinoside and fludarabine for treatment of adults with recurrent, refractory, or poor prognosis AML. Blood 1993; 82:131a. |
23. Robins HI, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Longo W, d’Oleire F. Phase I clinical trial of melphalan (L-PAM) and 41.8C whole body hyperthermia (WBH) in cancer patients. Anticancer Res 1995; abs. #194, 15:2449. |
24. Ratanatharathorn V, Nash RA, Devine SM, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW, Nademanee AP, Antin JH, Karanes C, Avalos BR, Christiansen NP, van der Jagt RH, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing Tacrolimus (Prograf®, FK506) with cyclosporine for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling bone marrow transplantation (BMT). Blood 1996; 88:459a. |
25. Wiedemann GJ, Katschinski DM, Mentzel M, Touhidi R, Feyerabend T, Wagner T, Rietbroek RC, Van der Zee J, Knuth A, Jaeger E, Jaeger D, van Heek-Romanowski R, Havers W, Cohen JD, Grosen EA, Gillis W, d’Oleire F, Longo W, Robins HI. Fire & ice: 48.8C whole body hyperthermia (WBH) with ifosfamide, carboplatin, & etoposide. Accepted, Radiation Research Society 45th Annual Meeting, 1997 and North American Hyperthermia Society 16th Annual Meeting 1997. |
26. Gordon MS, Young ML, Tallman M, Bennett J, Paletta E, Cripe L, Longo W, Gerad H, Banerjee T, Rowe J. Phase II trial of 2-chlorodeoxyadenosine (2-CdA) in patients (PTS) with relapsed/refractory acute myeloid leukemia (AML). Blood 1997; 90:242b. |
27. Mineishi S, Longo W, Atkinson ME, Smith EP, Wiersma S, Kinsella T, Hamielec M, and Scheuning FG. Addition of ARA-C to a cytoxan/TBI containing condition regimen decreases incidence of leukemic relapse without increase in toxicity. Blood 1997; 90:374a. |
28. Robins HI, Wiedemann GJ, Katschinski DM, Grosen EA, Mentzel M, Touhidi R, Feyerabend T, Wagner T, Rietbbroek RC, van der Zee J, Knuth A, van Reek Romanowski R, Cohen JD, Gillis W, d’Oleire F, Longo W, Spriggs D, Tiggelaar CL. 41.8C whole body hyperthermia (WBH): Current status and future prospects. Proc European Society for Hyperthermic Oncology (ESHO), 1997. |
29. Krueger D, Flynn B, Vallarta-Ast N, Smith EP, Atkinson ME, Longo W, Binkley N. Skeletal changes occur rapidly following allogeneic bone marrow transplantation. Oral presentation at the Post Transplantation Bone Disease Working Group 3rd Annual Meeting (22nd American Society for Bone and Mineral Research Annual Meeting). J Bone Miner Res 15(suppl 1):S420, 2000. |
30. Garry McCoy A, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett MB, Mitchell TL, Gangnon R, Longo WL. High dose thiotepa and etoposide: Long term experience with a novel conditioning regimen for autologous BM/PBPC transplant in 65 NHL patients. Blood 2001; 98(11). |
31. Black JM, Williams EC, Schwartz BS, Turman NJ, Mosher DF, Kahl BS. Long term experience using heparin and epsilon aminocaproic acid for the coagulopathy associated with acute promyelocytic leukemia. Blood 2002; 100:255b. |
32. Fenske TS, Kahl BS, Smith EP, Atkinson ME, Garry-McCoy A, Flynn B, McMannes J, Eikhoff J, Longo WL. High dose therapy with thiotepa, etoposide, and total body irradiation followed by autologous stem cell rescue for indolent and mantle cell lymphoma. Blood 2002; 100:471b. |
33. Kujawski L, Longo WL, Williams EC, Turman NJ, Brandt N, Kahl BS. High dose CHOP and midcycle methotrexate for adult Burkitt and Burkitt-like lymphomas. Blood 2002; 100:779a. |
34. Kahl BS, Bailey HH, Petroni G, Jaslowski A, Bayer G, Blank J, Bottner W, McGovern J, Smith J, Turman N, Werndli J, Longo WL. Phase II pilot study of modified hyper-CVAD plus rituximab for previously entreated mantle cell lymphoma: A Wisconsin oncology network study. Blood 102(11):290B-290B Part 2 2003. |
35. Chang JE, Juckett MB, Kahl BS, Mitchell TL, Gangnon RE, Callander NS, Longo WLL. Thalidomide (THAL) maintenance following high-dose melphalan with autologous stem cell transplant (ASCT) for myeloma. Blood 2006; 108:459b (abstr 5455). |
36. Buehring B, Krueger D, Engelke J, Flynn B, Longo W, Binkley N. Long-term follow-up
of bone mineral density, bone turnover markers and 25-hydroxyvitamin D in bone marrow transplant survivors. Poster presented at American Society for Bone and Mineral Research 29th Annual Meeting, Exploring New Horizons, Hawaii Convention Center, Honolulu, Hawaii, September 16-19, 2007.
|
37. Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL.
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma 2008;8(3):153-158.
|
38. Ninos c, Jared J, Mably M, Reed M, Hutson P, Williams Z, Callander NS, Hall AC, Juckett MB, Longo WL, Keukre VP. Outcomes of BeEAM (bendamistine, etoposide, cytarabine, melphalan) compared to BEAM (carmustine, etposide, cytarabine, melphalan) for High Dose Chemo Therapy followed by Autologous stem cell treatment. 2018. |
39. Kenkree VP, Juchett MB, Bradley K, Grindle K, Burkholder J, NBechville J, Callander NS, Hall AC, Longo WL, Hematti P. Engraftment and immune reconstitution outcomes after alpha/beta T cell and CD19 + B Cell Depletion with Haplodentical Transplantation in adult patients with Lymphoma. 2018.
|
40. Gahvari Z, Eickhoff J, Hall AC, Hematti P, Juckett M, Kenkre P, Longo WL, Callander NS. Failure of Levofloxacin Prophylaxis to Alter Incidence of Neutropenic Fever in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation. 2018. |
